WEBVTT

00:00:01.530 --> 00:00:03.048
Susannah de Jager: Welcome to Oxford+.

00:00:03.050 --> 00:00:06.690
The podcast series for innovators
and investors brought to you in

00:00:06.690 --> 00:00:08.333
partnership with Mishcon de Reya.

00:00:08.810 --> 00:00:12.950
Our guest today is Zandy Forbes,
CEO, and co-founder of MeiraGTx.

00:00:13.350 --> 00:00:17.495
MeiraGTx is a NASDAQ listed clinical
stage genetic medicine company

00:00:17.795 --> 00:00:21.755
pioneering innovative gene therapies
for both rare and prevalent diseases.

00:00:22.595 --> 00:00:25.825
It's headquartered in New York with
manufacturing in the UK and Ireland.

00:00:26.425 --> 00:00:29.935
Zandy started her career as an
academic with a double first in

00:00:29.935 --> 00:00:33.415
Natural Sciences from Cambridge
University and a PhD in Molecular

00:00:33.415 --> 00:00:35.275
Genetics from the University of Oxford.

00:00:35.425 --> 00:00:38.755
She was hired into the buy side
of a healthcare focused hedge fund

00:00:38.755 --> 00:00:42.685
Galleon, where she learn and operated
for over a decade as an analyst

00:00:42.685 --> 00:00:46.676
and portfolio manager appraising
biotech value and market forces.

00:00:47.396 --> 00:00:52.706
She co-founded MeiraGTx in 2015, and
is that unusual CEO that is equally

00:00:52.706 --> 00:00:56.396
comfortable discussing the assets
with scientists as she is the business

00:00:56.396 --> 00:00:58.526
strategy and share price with investors.

00:00:58.822 --> 00:01:01.122
Zandy, thank you so
much for joining today.

00:01:01.248 --> 00:01:06.348
So you've got such an interesting
background, having moved from academia

00:01:06.618 --> 00:01:12.378
to a fund manager role, and then now
as a CEO of a listed Biotech company.

00:01:13.218 --> 00:01:16.698
I'm fascinated to know what
has compelled you at each stage

00:01:16.728 --> 00:01:18.558
to move from one to the other?

00:01:18.558 --> 00:01:21.258
What is it that draws
you into the new domain?

00:01:21.939 --> 00:01:28.059
Zandy Forbes: That's an interesting
question and my personality is to make

00:01:28.989 --> 00:01:36.309
very big life changing decisions almost
instantly with very little information.

00:01:37.749 --> 00:01:46.569
What I really have learned from each
of those having moved what the value

00:01:46.749 --> 00:01:48.879
of the previous thing provided.

00:01:50.079 --> 00:01:56.019
I would say that when I was an
academic, I had done a PhD and I

00:01:56.019 --> 00:02:01.309
wanted to continue, discovering more
about the work that I'd done, and

00:02:01.459 --> 00:02:03.799
being an academic was what I knew.

00:02:04.349 --> 00:02:07.889
But I never saw myself as
doing that in the future.

00:02:08.669 --> 00:02:16.004
I was introduced to the hedge fund
manager, a very large fund, by chance and

00:02:16.244 --> 00:02:18.584
I had never met anyone on Wall Street.

00:02:18.584 --> 00:02:23.714
I was coming back to England to set
up an academic lab, and I managed

00:02:23.714 --> 00:02:29.144
to find one person on Wall Street
that someone, a friend of mine from

00:02:29.144 --> 00:02:34.784
England, knew his wife and I thought,
well, I better phone this person and

00:02:34.784 --> 00:02:37.264
find out what even is a hedge fund.

00:02:38.134 --> 00:02:44.484
So I called this guy and he started
talking in Wall Street jargon about steep

00:02:44.484 --> 00:02:46.114
learning curves and blah, blah, blah.

00:02:46.764 --> 00:02:50.874
And then he suddenly
went, what fund is this?

00:02:51.054 --> 00:02:52.049
That's offered you a job?

00:02:53.469 --> 00:02:58.989
And I was a little bit sheepish, a
because they'd offered me a job and I

00:02:58.989 --> 00:03:04.029
knew absolutely nothing, and b, because
when I'd visited it, it was, the trading

00:03:04.029 --> 00:03:11.150
floor with, people playing foosball and
they were really loud and they looked

00:03:11.150 --> 00:03:12.350
like they were playing games, right.

00:03:12.845 --> 00:03:13.595
And so I thought, what?

00:03:13.595 --> 00:03:14.645
What is this fund?

00:03:14.645 --> 00:03:16.715
I've never been anywhere near Wall Street.

00:03:17.195 --> 00:03:21.445
And I said the name of the
fund, and he went silent.

00:03:21.805 --> 00:03:25.675
And he went, oh my God,
that's my biggest client.

00:03:26.515 --> 00:03:26.575
I want that job.

00:03:27.145 --> 00:03:35.125
So the truth of the matter is I took the
job because I saw a world of adventure

00:03:35.455 --> 00:03:40.615
and excitement and interest, a world
that was big outside anything I knew

00:03:40.915 --> 00:03:43.735
and someone else told me they wanted it.

00:03:43.998 --> 00:03:45.798
Susannah de Jager: That's
exceptionally honest.

00:03:45.798 --> 00:03:46.458
I love that.

00:03:46.668 --> 00:03:52.488
But it does also speak to how much
personal recommendation that's such a high

00:03:52.488 --> 00:03:57.558
currency, so I don't think it's the worst
bellwether to have paid attention to.

00:03:57.899 --> 00:04:02.709
Zandy Forbes: And I think the last
thing I said, which is when I went

00:04:02.709 --> 00:04:08.909
to meet the fund manager, he actually
gave me the IPO prospectuses of three

00:04:08.909 --> 00:04:14.999
companies, Agenix, Medex, and Exelixis,
and I was a fruit fly geneticist.

00:04:15.449 --> 00:04:19.259
All the fruit fly genes had been
discovered in a big screen Nobel

00:04:19.259 --> 00:04:24.229
Prize was given and scientists were
given genes and you are very focused

00:04:24.229 --> 00:04:28.189
on your little area, and I continued
to work on that over the decade.

00:04:28.489 --> 00:04:34.189
However, when I saw the prospectuses
of these three companies, particularly

00:04:34.189 --> 00:04:40.939
this company Exelixis, they had
identified every single fly gene.

00:04:41.209 --> 00:04:44.749
They had every C. elegans
gene, they had mice.

00:04:44.959 --> 00:04:53.239
So they were looking at everything and
I suddenly realized that science is

00:04:55.324 --> 00:05:01.174
not the spec that we all in our labs
are looking at in great detail, but

00:05:01.234 --> 00:05:03.520
literally it was like mind blown.

00:05:04.090 --> 00:05:07.396
A company is doing it all.

00:05:07.440 --> 00:05:11.715
That was really interesting to me
cause it was completely unknown.

00:05:11.820 --> 00:05:15.129
I had no idea that there were
companies let alone that did

00:05:15.249 --> 00:05:17.589
everything that all of us do and more.

00:05:18.036 --> 00:05:22.326
Susannah de Jager: And it's so fascinating
because now hearing that description of

00:05:22.356 --> 00:05:26.526
your whole perspective being changed of
how this could be applied, the vectors

00:05:26.526 --> 00:05:30.126
through which it might come to the
real world, just the reality of those

00:05:30.126 --> 00:05:32.256
companies, as you say, being in existence.

00:05:32.466 --> 00:05:36.126
It's quite hard to imagine because
now that dislocate between academia

00:05:36.126 --> 00:05:40.416
and people aiming for translational
science is so much smaller.

00:05:40.416 --> 00:05:44.176
That's the aspiration of
many a budding scientist.

00:05:44.246 --> 00:05:48.236
Zandy Forbes: That's an interesting
comment because in 2000, which was the

00:05:48.236 --> 00:05:53.176
year that this occurred, it was in the
time of the genome being sequenced,

00:05:53.566 --> 00:06:01.666
these companies were not developing a
particular drug to go to the clinic.

00:06:02.026 --> 00:06:06.856
Each of the companies I've
mentioned provided a platform

00:06:07.246 --> 00:06:09.796
for looking at all genes.

00:06:09.864 --> 00:06:11.664
All cell surface antibody.

00:06:11.724 --> 00:06:13.344
All cell surface molecules.

00:06:14.424 --> 00:06:16.644
All antibodies that humans could make.

00:06:17.034 --> 00:06:26.274
So it was as if all of academia
was condensed into one company.

00:06:27.114 --> 00:06:36.678
Now today, each little academic project
gets turned into potentially a therapeutic

00:06:36.768 --> 00:06:39.228
which can be approved and un marketed.

00:06:39.588 --> 00:06:46.173
So, while it looks like there was
such a big difference between academia

00:06:46.413 --> 00:06:52.263
and industry at the time, I'll come
back to the company, Exelixis, that

00:06:52.263 --> 00:06:54.453
did genetics across all animals.

00:06:55.263 --> 00:07:00.963
Many people, it turned out from my
PhD lab and the fly genetic world and

00:07:00.963 --> 00:07:02.958
the C. elegans were working there.

00:07:03.627 --> 00:07:08.952
Susannah de Jager: Very interesting,
and so you did move into this world

00:07:09.297 --> 00:07:14.319
and then after 10 years, you moved
again to run one of these companies.

00:07:15.269 --> 00:07:17.879
Tell us a bit about MeiraGTx.

00:07:17.949 --> 00:07:23.019
Zandy Forbes: MeiraGTx is a genetic
medicines company, and why I say genetic

00:07:23.019 --> 00:07:28.299
medicines rather than gene therapy is
because there are many companies that

00:07:28.569 --> 00:07:36.924
do gene therapy, and that word has
come to mainly mean, you look at people

00:07:36.924 --> 00:07:41.874
with a broken gene, for example, an
inherited disorder, and they're often

00:07:41.874 --> 00:07:47.484
very severe and rare, and you take a
gene and you put it back into those

00:07:47.484 --> 00:07:54.814
people, babies to adults, hopefully
replace that function and replace that

00:07:54.814 --> 00:08:00.454
gene in a way that allows those people
to have a normal life, let's say.

00:08:00.934 --> 00:08:02.404
So it's gene replacement.

00:08:02.944 --> 00:08:10.504
However, when we started Meira while gene
replacement is something we do for certain

00:08:10.504 --> 00:08:18.094
indications, the aim of the company was
to build a way that you can make the

00:08:18.094 --> 00:08:22.234
body, make any biologic therapeutic.

00:08:23.014 --> 00:08:29.524
And what that means is using
DNA as a template in the body.

00:08:29.584 --> 00:08:34.294
DNA that you've made in the body
may be injected locally to the

00:08:34.294 --> 00:08:39.684
muscle activating that DNA to make
RNA and make protein with a pill.

00:08:40.434 --> 00:08:46.659
So the idea, which had never been done
before is, all of the biologics, which

00:08:46.659 --> 00:08:55.039
are huge number of drugs for psoriasis
and many autoimmune diseases, antibodies,

00:08:55.159 --> 00:09:01.339
all of those drugs, and by the way,
all of the gut peptides, GLP-1 GIP,

00:09:01.399 --> 00:09:09.139
glucagon, amylin, leptin, all of those
come from DNA in the body, and what we

00:09:09.139 --> 00:09:12.499
wanted to do is take those DNA sequences.

00:09:13.174 --> 00:09:18.334
Put our own controlled version of
those genes locally into somewhere

00:09:18.334 --> 00:09:23.884
like the muscle, and then you take a
pill and you make GLP-1 at the right

00:09:23.884 --> 00:09:27.214
time of day at the right sort of drug.

00:09:27.214 --> 00:09:28.894
Not long acting, for example.

00:09:29.344 --> 00:09:35.014
And so the body turns into the
manufacturing facility, I suppose the

00:09:35.014 --> 00:09:40.354
manufacturing site for the drug, any
biologic drug, and the pill is the

00:09:41.284 --> 00:09:45.244
activator, which gives you exactly the
right dose at exactly the right time.

00:09:45.784 --> 00:09:51.329
So this enables you to use DNA
in many, many ways, not just

00:09:51.454 --> 00:09:56.584
to replace broken genes, but to
deliver any protein you want to.

00:09:57.394 --> 00:10:04.924
And in between those two things, there
are ways that you can use DNA in the

00:10:04.924 --> 00:10:10.564
nervous system, for example, to change
the circuitry of the brain by delivering

00:10:10.624 --> 00:10:15.874
tiny doses that change neurotransmitters
in koilocyte, and we've actually done

00:10:15.874 --> 00:10:23.584
that in Parkinson's, and we have shown
in our controlled studies that we have

00:10:23.704 --> 00:10:29.854
benefits on Parkinson's when the drugs
aren't working and using AI, we now

00:10:29.854 --> 00:10:32.104
seem to have a disease modifying effect.

00:10:32.104 --> 00:10:37.444
We change the brain of Parkinson's
patients and allow them to move and maybe

00:10:37.474 --> 00:10:40.174
it looks like slow their degeneration.

00:10:41.074 --> 00:10:46.924
So we had a vision that was a little
bit different from just replacing

00:10:46.924 --> 00:10:52.384
genes, which we do in the eye all the
way through to delivering any of the

00:10:52.384 --> 00:10:53.624
biologic drugs that are out there.

00:10:54.246 --> 00:10:57.396
Susannah de Jager: Kind of mind blowing
when you hear it described so simply.

00:10:57.637 --> 00:11:01.717
Zandy Forbes: It is mind blowing and
the most mind blowing thing, by the

00:11:01.717 --> 00:11:08.887
way, this being able to take any gene
for any drug you like, put it into the

00:11:08.887 --> 00:11:12.997
body so it's a little manufacturing
facility and switch it on with a pill.

00:11:14.407 --> 00:11:16.327
We have no idea how to do that.

00:11:16.942 --> 00:11:22.162
People had tried for years to use
switches from bacteria to design switches

00:11:22.162 --> 00:11:25.732
that controlled gene expression and
no one had been able to do it well.

00:11:26.302 --> 00:11:29.782
They could vaguely switch things
on like double expression or

00:11:29.782 --> 00:11:33.682
something over five to 10 years.

00:11:33.927 --> 00:11:43.252
We rather amazingly have developed
a system for really precisely dosing

00:11:44.812 --> 00:11:51.982
the production of a drug in the
body that is so exquisitely tight

00:11:52.192 --> 00:11:59.692
that one small molecule makes one
RNA, and we can exactly control the

00:11:59.692 --> 00:12:01.402
amount of that drug that's made.

00:12:02.062 --> 00:12:05.872
Now, we didn't know that we could do
that, and that was invented in house.

00:12:05.872 --> 00:12:10.612
It's very, very unusual for
a biotech company to actually

00:12:11.242 --> 00:12:12.832
invent their technology.

00:12:13.417 --> 00:12:16.417
This was very speculative.

00:12:16.717 --> 00:12:20.587
That's why when we started the company,
we didn't say, oh, we are going to

00:12:20.587 --> 00:12:24.747
make, the new delivery mechanism
for all therapeutics a biologic.

00:12:25.017 --> 00:12:28.017
We actually said, we're starting gene
therapy company and we're going to

00:12:28.017 --> 00:12:33.387
start with gene replacement in the
eye, local delivery in the brain,

00:12:33.567 --> 00:12:38.367
local delivery in the salary glands,
cause we didn't want to give huge

00:12:38.367 --> 00:12:41.157
doses, which can be toxic to people.

00:12:41.157 --> 00:12:45.867
We just wanted tiny doses in local
places that had a big difference

00:12:46.077 --> 00:12:50.637
to the physiology of the cells that
they were touching, and we have four

00:12:50.637 --> 00:12:54.957
late stage programs now, all of which
are small, local delivery doses.

00:12:55.437 --> 00:13:01.017
The whole time we were working on the
new massive mind blowing technology

00:13:01.467 --> 00:13:03.627
to take over the biologics industry.

00:13:05.159 --> 00:13:07.589
Susannah de Jager: And so tell us a
bit about the four drugs that you have.

00:13:07.589 --> 00:13:09.989
Cause I think it's really interesting
for people to hear how you are

00:13:09.989 --> 00:13:10.919
currently looking to apply this.

00:13:11.909 --> 00:13:18.599
Zandy Forbes: So I mentioned that when we
started the company, we decided to only

00:13:19.359 --> 00:13:26.709
use very small doses, locally delivered,
and that is in contrast to many gene

00:13:26.709 --> 00:13:32.889
therapies, gene replacement, right in
inherited disorders like hemophilia or

00:13:32.889 --> 00:13:41.144
Duchenne's, where massive, massive doses
are given IV for enough of the gene to

00:13:41.144 --> 00:13:45.694
get to the appropriate tissue, whether
it's liver or muscle, and that has worked

00:13:45.694 --> 00:13:48.514
in some cases in very severe diseases.

00:13:48.754 --> 00:13:54.649
However, to us, I wasn't
comfortable taking that risk

00:13:54.649 --> 00:13:56.209
to do something that hard.

00:13:56.479 --> 00:14:03.019
It's very hard to do, and there
are broad, potential toxicities

00:14:03.019 --> 00:14:07.339
of doing that and people have been
successful, but it's not easy.

00:14:08.209 --> 00:14:16.279
And so in contrast to that, we wanted
to use tiny doses and in very specific

00:14:16.279 --> 00:14:22.279
spots, and it allowed us to actually
manufacture all the material we use.

00:14:22.939 --> 00:14:27.919
So where we went first is in the eye,
because it's locally delivered to

00:14:27.919 --> 00:14:34.739
the back of the eye and a number of
inherited retinal diseases, one we sell

00:14:34.739 --> 00:14:40.989
to Johnston & Johnson, and that has very
strong data in certain endpoints in a

00:14:40.989 --> 00:14:45.189
phase three, and that's awaiting BLA.

00:14:46.059 --> 00:14:51.889
We actually, for charity,
interestingly, created a gene

00:14:51.889 --> 00:14:57.919
therapy, so gene replacement for the
most aggressive and earliest form

00:14:57.919 --> 00:15:00.109
of inherited blindness in children.

00:15:00.109 --> 00:15:06.754
So it's so early that babies are born
completely blind, and this is unlike

00:15:06.754 --> 00:15:12.724
most inherited retinal disease where you
degenerate to blindness over the years.

00:15:13.144 --> 00:15:15.274
So you've got children born blind.

00:15:15.364 --> 00:15:16.624
It's ultra rare.

00:15:16.954 --> 00:15:18.454
You can't do a clinical trial.

00:15:18.634 --> 00:15:23.674
So we have a manufacturing license
in the UK that allowed us to

00:15:23.674 --> 00:15:28.819
release material that physicians
could then give the injection into

00:15:28.819 --> 00:15:30.289
the back of the eye to these kids.

00:15:31.099 --> 00:15:33.739
So four children were
treated only in one eye.

00:15:34.459 --> 00:15:37.999
Every one of those children went
from blind to being able to see.

00:15:38.419 --> 00:15:39.859
Properly being able to see.

00:15:41.389 --> 00:15:44.959
Another seven children were treated
this time because it was so safe

00:15:45.169 --> 00:15:52.159
in both eyes, and this was in two
expert hospitals in London and all 11

00:15:52.159 --> 00:15:56.254
children blind when born seeing now.

00:15:56.584 --> 00:15:58.474
We've got videos, we've got everything.

00:15:58.924 --> 00:16:08.134
So this data was so extraordinary that
the UK regulators suggested we file for

00:16:08.134 --> 00:16:14.134
approval under exceptional circumstances,
which is what we're doing, and we are

00:16:14.134 --> 00:16:21.444
a manufacturer that will be commercial
and that is allowing us to actually

00:16:21.469 --> 00:16:25.759
file with manufactured commercial
material that we make ourselves.

00:16:26.299 --> 00:16:34.451
We are in dialogue with the FDA and they
too have given us a pathway to filing

00:16:34.451 --> 00:16:38.591
this for approval in a similar fashion.

00:16:38.981 --> 00:16:47.051
So we're going down both pathways this
year to be able to file this drug that

00:16:47.666 --> 00:16:50.456
has absolutely extraordinary efficacy.

00:16:50.506 --> 00:16:54.976
No one's ever seen anything like
this before in gene replacement.

00:16:56.566 --> 00:17:00.316
However, we treated people
under the age of four.

00:17:00.316 --> 00:17:03.346
You can't treat them later than four
because their whole retina is degenerated.

00:17:03.856 --> 00:17:07.906
So it shows you that if you
can treat these kids early

00:17:07.906 --> 00:17:10.546
enough, you get massive benefit.

00:17:10.726 --> 00:17:13.501
Maybe in other diseases
of the eye as well.

00:17:14.461 --> 00:17:18.171
In this particular case, the guys at the
Moorefield said this is their career.

00:17:18.681 --> 00:17:23.361
It's a defining moment for them and
it really is amazing when you see the

00:17:23.361 --> 00:17:28.173
videos of the kids, they're absolutely
great and in fact, the videos of

00:17:28.173 --> 00:17:32.733
the parents are amazing because it's
not just the drug, it's the parents

00:17:32.913 --> 00:17:36.093
that drive this for their children.

00:17:37.048 --> 00:17:41.728
And this was all done in the UK
because we have a specialist license

00:17:41.728 --> 00:17:44.188
that allowed us to do it, and
now we're bringing it to the US.

00:17:46.468 --> 00:17:50.813
The other two diseases are
Parkinson's that I mentioned.

00:17:51.023 --> 00:17:52.883
That's in a Phase Three study.

00:17:53.153 --> 00:17:59.153
We have two sham controlled, so that's
placebo double-blind studies, which

00:17:59.153 --> 00:18:04.163
shows this improves movement in people
who no longer respond to dopamine.

00:18:04.163 --> 00:18:05.723
So there's nothing you can really do.

00:18:06.323 --> 00:18:08.093
That's very unusual.

00:18:08.093 --> 00:18:13.283
We're the only genetic medicine,
cell therapy, growth factor therapy,

00:18:13.583 --> 00:18:19.193
studies that have ever shown a benefit
against a placebo sham control.

00:18:20.123 --> 00:18:25.583
We have now used AI that comes out
of Queen Square and welcome to look

00:18:25.583 --> 00:18:31.733
at that double blind data, the scans,
and we can see we have significantly

00:18:31.733 --> 00:18:36.983
changed the circuitry of the brain,
and we have changed the input to the

00:18:36.983 --> 00:18:41.243
substantial nigra, which is the area
that degenerates in Parkinson's.

00:18:41.573 --> 00:18:46.613
So we believe we are not only
affecting symptoms, but we may have

00:18:46.613 --> 00:18:49.403
the chance to slow Parkinson's itself.

00:18:49.588 --> 00:18:55.684
Finally, we treat something called
Xerostomia, which is the lack of

00:18:55.684 --> 00:19:00.484
saliva production after you've been
treated for head and neck cancer.

00:19:00.771 --> 00:19:05.185
Everyone loses saliva,
however, 30% never get it back.

00:19:05.575 --> 00:19:10.255
They lose their teeth, they can't speak,
they can't swallow, and it's a really

00:19:10.255 --> 00:19:14.570
nasty condition two years after you've
been cured of head and neck cancer.

00:19:15.685 --> 00:19:20.615
We're able to locally just put water
channel genes into this salivary

00:19:20.635 --> 00:19:23.035
glands and water is produced.

00:19:23.335 --> 00:19:26.575
We've done a Phase One
dose escalating study.

00:19:27.115 --> 00:19:34.105
We are in the middle of a Phase Two study,
which is double blind, which the FDA have

00:19:34.105 --> 00:19:40.642
given us a designation called R MAT and
have aligned with us that this can be an

00:19:40.642 --> 00:19:44.707
approval supporting Phase Three study.

00:19:45.367 --> 00:19:47.762
So that's where we are with
all of our four programs.

00:19:49.297 --> 00:19:51.412
Susannah de Jager: Very different,
which I think articulates the point

00:19:51.502 --> 00:19:55.882
you made already, which is just how
broad the platform that you have is.

00:19:56.042 --> 00:19:58.989
But you've also created
manufacturing facilities.

00:19:59.425 --> 00:20:03.685
I just wanted to draw you on that
because having been a fund manager

00:20:03.985 --> 00:20:07.192
and having analyzed companies,
that have perhaps a single asset.

00:20:08.617 --> 00:20:12.037
I know from our conversation that
you have designed your company not

00:20:12.037 --> 00:20:17.017
to be that way and to have less of
a binary outcome on any one asset.

00:20:17.707 --> 00:20:21.828
I'd love to hear that strategy from
you a bit and how you think about that.

00:20:22.179 --> 00:20:22.839
Zandy Forbes: Yes.

00:20:23.039 --> 00:20:28.608
I think if we go back to my nature, just
for a minute, and it applies to both being

00:20:28.608 --> 00:20:31.428
a fund manager and running a company.

00:20:32.328 --> 00:20:38.208
And in fact, one of the reasons I
took the fund manager job is because

00:20:38.718 --> 00:20:43.808
I am fundamentally adventurous.

00:20:44.255 --> 00:20:49.867
However, to be honest, I
am also incredibly fearful.

00:20:50.782 --> 00:20:53.212
So it's a weird balance, right?

00:20:53.512 --> 00:20:57.172
In personality, those are two
quite dominant features of me.

00:20:57.772 --> 00:21:01.882
In order to be super adventurous
as well as being super fearful,

00:21:02.212 --> 00:21:07.312
you have to have developed risk
mitigation tools that you trust.

00:21:08.242 --> 00:21:17.032
I understood that in biology, in this
world of biotech, it's very difficult to

00:21:17.032 --> 00:21:27.472
legally have what you are told you need
to have, which is certainty and an edge.

00:21:27.839 --> 00:21:29.729
That's a very, very
difficult thing to have.

00:21:30.989 --> 00:21:33.989
You think, well, if I'm a
biologist, if I'm a doctor, I'll

00:21:33.989 --> 00:21:36.629
be able to tell better than other
people if this is going to work.

00:21:36.719 --> 00:21:37.019
No.

00:21:37.919 --> 00:21:43.799
So there was a recognition from being
a fund manager that there is a huge

00:21:43.799 --> 00:21:50.429
amount that we don't know in biology,
that we can't predict in biology, that

00:21:50.429 --> 00:21:55.389
we can't predict in regulatory agencies
cause we don't see the information.

00:21:55.986 --> 00:22:03.576
So there were many ways of layering
risk management, like what positions

00:22:03.576 --> 00:22:14.486
you had, how we hedged them, but
seeing a portfolio as almost a moving

00:22:14.486 --> 00:22:18.611
sculpture of risk and reward over time.

00:22:20.951 --> 00:22:28.391
Somehow that fed into a company
which couldn't, coming from me, be

00:22:28.541 --> 00:22:31.811
a one product, binary risk company.

00:22:33.041 --> 00:22:43.301
We had to build a real company and
provide investors while doing that certain

00:22:43.301 --> 00:22:47.181
binary events that they could invest in.

00:22:48.121 --> 00:23:01.481
So I would say that the company was built
more out of design for a company with the

00:23:01.481 --> 00:23:10.931
hope of a technology that we developed
than always making one product that will

00:23:10.931 --> 00:23:14.936
be a big product as the single asset.

00:23:15.336 --> 00:23:20.539
It's very difficult to do that and many
companies are successful, but many aren't,

00:23:20.599 --> 00:23:25.099
and I wanted this to be a resilient
company that we could go through the years

00:23:25.099 --> 00:23:30.049
and if we had failures, we'd have other
things that were successes as we built

00:23:30.049 --> 00:23:34.939
our technology, we could support that with
deals that we do with other companies.

00:23:35.189 --> 00:23:41.459
In the deals we do, one also has to
recognize what we can do and what a

00:23:41.459 --> 00:23:48.029
partner can do and what we can afford to
do and what partners can afford to do, and

00:23:48.149 --> 00:23:56.009
knowing how much it costs to get to the
point that you are really, really valuable

00:23:56.219 --> 00:24:02.009
and you are selling completely innovative
drugs has also driven those decisions.

00:24:03.329 --> 00:24:10.379
Because you have to be able to provide,
visibility on value each year, right?

00:24:11.219 --> 00:24:17.434
So new trials that work and maybe
doing it in different indications,

00:24:18.154 --> 00:24:21.514
always interacting with regulators
about everything you are doing.

00:24:22.234 --> 00:24:28.279
So that really describes I think
some of the risk mitigation in the

00:24:28.279 --> 00:24:33.319
company needed to be multi-layered
and making manufacturing was one of

00:24:33.319 --> 00:24:39.229
the things that has turned out to be
expensive but necessary for all of

00:24:39.229 --> 00:24:40.494
our products and indeed our partners.

00:24:41.409 --> 00:24:43.299
Susannah de Jager: Yeah,
and it makes perfect sense.

00:24:43.424 --> 00:24:47.204
In different market conditions you'll
have assets that are potentially in vogue

00:24:47.204 --> 00:24:49.844
that regulators are pushing through.

00:24:49.844 --> 00:24:51.194
Obviously then you can supplement.

00:24:51.194 --> 00:24:54.741
So I suppose what's surprising is that
more people don't build like this and that

00:24:54.741 --> 00:24:58.781
there are still so many single assets, but
they don't have your background, Zandy.

00:24:59.017 --> 00:25:04.252
Zandy Forbes: Most, I don't know if
most, but many companies, that are

00:25:04.252 --> 00:25:10.872
currently public, may have come from
academia that are often set up by

00:25:11.922 --> 00:25:17.022
either long short funds that are now
doing VC or very experienced VCs.

00:25:17.402 --> 00:25:21.182
There can, there are lots of different
VC models, some of them are, take a

00:25:21.182 --> 00:25:23.792
product, develop them, sell to pharma.

00:25:24.032 --> 00:25:27.872
Others are, take an academic
idea, put it into the clinic

00:25:28.112 --> 00:25:29.912
and get that drug approved.

00:25:29.942 --> 00:25:33.782
And those are, those have been
successful, however many haven't.

00:25:34.022 --> 00:25:34.382
Right?

00:25:34.802 --> 00:25:38.876
And when they aren't successful,
they trade below cash and

00:25:38.876 --> 00:25:40.196
then they may have to pivot.

00:25:40.586 --> 00:25:46.811
So it's a different way of
treating biotech, less about making

00:25:46.811 --> 00:25:52.241
companies and more about monetizing
products at different points.

00:25:52.650 --> 00:25:56.760
There are obviously platform companies
set up by VCs and there are also

00:25:56.760 --> 00:26:03.290
companies that were single products
that do deals and actually develop

00:26:03.470 --> 00:26:08.750
into revenue generating biotech
companies, and they are really valuable.

00:26:08.960 --> 00:26:11.702
They can be too valuable
for pharma to buy.

00:26:12.167 --> 00:26:21.407
I recently saw a talk by the CEO of
Instamed, and if you hear how that

00:26:21.407 --> 00:26:29.087
company developed from a one or two
product company through partnerships,

00:26:29.087 --> 00:26:31.397
through successes, through pivots.

00:26:32.537 --> 00:26:38.507
That's a company that, at every moment,
the management and the team have looked

00:26:38.507 --> 00:26:44.927
at where they are and made decisions
that have ended up with them being

00:26:45.317 --> 00:26:52.067
a very successful revenue generating
company that can develop into one

00:26:52.067 --> 00:26:53.657
of the really big biotech companies.

00:26:53.657 --> 00:26:55.757
So it's not all or nothing.

00:26:55.997 --> 00:27:02.247
But our perspective was maybe a bit
broad and looking to the future and

00:27:02.247 --> 00:27:04.167
we didn't really have VC investors.

00:27:04.697 --> 00:27:06.922
Susannah de Jager: Yeah, and you've
brought me exactly to where I was

00:27:06.922 --> 00:27:10.312
hoping we would land next, which is
you've spoken about the investment

00:27:10.312 --> 00:27:16.852
needed to grow a company like this and
you chose to list on the NASDAQ, and

00:27:16.852 --> 00:27:21.742
I would just love to hear what drove
that decision from your perspective.

00:27:21.832 --> 00:27:25.692
Particularly given that you had
been a fund manager, so you are even

00:27:25.692 --> 00:27:29.232
more knowledgeable than most CEOs
would ever have been at that point.

00:27:29.712 --> 00:27:32.532
Zandy Forbes: So we did go public
quite quickly, at a time when

00:27:32.532 --> 00:27:40.625
there are many, many IPOs and we
had very little VC investment.

00:27:41.315 --> 00:27:49.115
I think that's more because that
wasn't my experience, right?

00:27:49.195 --> 00:27:55.660
There's a different way of having
dialogue with VCs, maybe from public

00:27:55.660 --> 00:28:00.610
investors, which is what I'd been
for a decade, and I just wasn't

00:28:00.610 --> 00:28:03.790
familiar with the private VC world.

00:28:04.750 --> 00:28:08.050
That doesn't mean we
didn't, we avoided them.

00:28:08.080 --> 00:28:08.620
We didn't.

00:28:08.620 --> 00:28:13.600
It just wasn't something that I was
particularly comfortable with in

00:28:13.600 --> 00:28:21.820
comparison to the comfort of the public
markets, and I think that sentence in and

00:28:21.820 --> 00:28:25.150
of itself is weird for people to hear.

00:28:25.630 --> 00:28:30.970
But having been an analyst portfolio
management manager and probably,

00:28:31.210 --> 00:28:35.740
I don't know how many, one-on-ones
I've been to thousands, right?

00:28:36.007 --> 00:28:43.057
With other funds, so many meetings
over a decade, that from my

00:28:43.057 --> 00:28:51.337
perspective, the public market
investors are unbelievably courteous.

00:28:52.477 --> 00:28:58.867
There is a known way of speaking that
you each know what you are saying

00:28:58.867 --> 00:29:03.277
to one another, which is something
I understood having been one.

00:29:04.117 --> 00:29:08.407
I have a lot of respect for many
of the public market investors.

00:29:09.202 --> 00:29:14.662
Some of whom have been doing it for
20 years, and they are knowledgeable

00:29:14.812 --> 00:29:18.412
about the whole of the pharma industry.

00:29:18.562 --> 00:29:20.272
Like all of the drugs.

00:29:20.422 --> 00:29:22.132
All of the pharma companies.

00:29:22.162 --> 00:29:23.662
All of the biotechs that have failed.

00:29:23.962 --> 00:29:31.212
These guys know so much and I now
know how much they know because when I

00:29:31.212 --> 00:29:35.947
stopped doing it 10 years ago and went
into industry, I'm like, oh my God.

00:29:35.977 --> 00:29:40.237
But I've watched so many FDA
panels, I've seen so many failures.

00:29:40.447 --> 00:29:46.237
I've learned so much, and those same
guys have continued for another decade.

00:29:46.627 --> 00:29:55.727
So there is a personal comfort
and respect, from me with public

00:29:56.477 --> 00:30:02.705
investors that comes from me having
been one and I think it's justified.

00:30:03.120 --> 00:30:08.280
They have to make decisions every
minute based on only the knowledge

00:30:08.280 --> 00:30:13.650
they have right there and then, cause
every minute you either are holding,

00:30:14.250 --> 00:30:19.380
selling, or buying a stock, you don't
get to do another bit of diligence

00:30:19.380 --> 00:30:21.090
and come back two weeks later.

00:30:21.780 --> 00:30:27.690
And so, not only is there a lot of
knowledge, there's a lot of history,

00:30:28.170 --> 00:30:33.630
and there's the ability to make
decisions without all the information.

00:30:33.979 --> 00:30:35.989
Susannah de Jager: For you it
was a given that you would list

00:30:35.989 --> 00:30:37.849
on the NASDAQ and not in the UK.

00:30:38.105 --> 00:30:41.555
I'd love you to illuminate on that because
obviously it's a really live discussion.

00:30:41.870 --> 00:30:45.470
It seems to me it's very hard for the
UK to compete in this area with the

00:30:45.470 --> 00:30:48.085
depth and the longevity of the market.

00:30:48.145 --> 00:30:49.165
But I'd love to hear it from you.

00:30:50.623 --> 00:30:57.083
Zandy Forbes: So the UK has great
universities and they're really good

00:30:57.083 --> 00:31:02.843
at inventing things and there is a
push to monetize those inventions.

00:31:04.523 --> 00:31:07.193
Our eye products we license from UCL.

00:31:08.243 --> 00:31:09.473
Great science.

00:31:09.803 --> 00:31:13.643
Many people moved from UCL to our company.

00:31:13.823 --> 00:31:18.053
We work closely with Moorfield, really the
best eye hospital in the world, I'd say.

00:31:18.725 --> 00:31:21.695
There's definitely opportunity in the UK.

00:31:22.160 --> 00:31:28.716
It is hard to work with any
university, whether it's US, UK

00:31:28.956 --> 00:31:32.886
or globally, to do deals and slow.

00:31:34.086 --> 00:31:38.616
So I don't think that
distinguishes the uk right?

00:31:38.886 --> 00:31:47.384
But I would say the amounts of money
over certain periods of time that

00:31:47.384 --> 00:31:56.564
actually required that get from an
academic drug or idea to a Phase Three

00:31:56.564 --> 00:32:05.774
product and the infrastructure that
is required, just it's too large for

00:32:06.224 --> 00:32:13.484
the UK biotech capital markets, right?

00:32:15.044 --> 00:32:23.588
So our manufacturing, which is enabled
all of our products and we have one of the

00:32:23.588 --> 00:32:30.953
best, most, probably the best end to end,
gene therapy manufacturing in the world.

00:32:31.223 --> 00:32:34.103
Starting with making the process.

00:32:34.103 --> 00:32:36.413
We make the plasmids, we make the vector.

00:32:36.623 --> 00:32:40.433
We even have a facility that's
commercially approved to do all the

00:32:40.433 --> 00:32:42.233
testing, so we can do everything.

00:32:42.233 --> 00:32:43.073
It's very unusual.

00:32:43.373 --> 00:32:44.993
We did it because we had to.

00:32:45.533 --> 00:32:47.483
It cost us hundreds of millions.

00:32:47.783 --> 00:32:50.003
A lot of that money we
got through partnership.

00:32:51.503 --> 00:32:59.663
That would've been very difficult to
do if we had only relied on UK capital

00:32:59.663 --> 00:33:04.123
markets because it's very large amounts.

00:33:04.913 --> 00:33:10.343
If you think of all the biotech
companies out there that are spending,

00:33:10.403 --> 00:33:17.003
that are raising hundreds of millions
for Series A, Series B. Number one,

00:33:17.063 --> 00:33:18.923
it's very large amounts, right?

00:33:19.763 --> 00:33:20.813
Number two is,

00:33:22.883 --> 00:33:27.743
going public in the UK just
doesn't have the ecosystem.

00:33:28.193 --> 00:33:36.443
It doesn't have the large numbers of
biotech expertise that is required and

00:33:36.443 --> 00:33:39.323
the trading volume that is required.

00:33:39.893 --> 00:33:44.873
People need liquidity in order
to trade on good news or bad.

00:33:46.448 --> 00:33:49.608
And it's not great at the NASDAQ at
the moment, the last three and a half

00:33:49.608 --> 00:33:55.051
years have not been great, and I can
only imagine with the reduced amount of

00:33:55.051 --> 00:34:02.941
capital and the reduced liquidity, what
it would feel like in the UK markets.

00:34:03.971 --> 00:34:07.721
It's not a rapid problem to solve.

00:34:08.231 --> 00:34:15.821
The UK could, in the next 20 years,
become a center of biotech, like

00:34:15.821 --> 00:34:23.111
Boston, like San Diego, if investors
start investing, if people start

00:34:23.111 --> 00:34:28.991
learning, if fund managers become
established, if the US starts investing.

00:34:29.021 --> 00:34:32.501
Cause they're the real experts over
the last 30 years in this industry.

00:34:33.051 --> 00:34:39.278
It's not that it can't happen,
but it can't happen in a year.

00:34:39.278 --> 00:34:46.678
It requires a lot of knowledge, knowhow
and persistence, and that can be done.

00:34:47.248 --> 00:34:52.078
Ireland did it in a whole different
way in manufacturing by educating,

00:34:52.078 --> 00:34:56.688
by changing policy and are one of
the best countries for manufacturing

00:34:56.928 --> 00:34:58.938
or have been over the last 20 years.

00:34:59.118 --> 00:35:05.598
Micheál Martin started, had this
idea 25 years ago, and the Irish,

00:35:05.628 --> 00:35:10.458
we have a facility in Ireland that
manufactures, they are incredibly good.

00:35:11.628 --> 00:35:14.953
They do degrees in running facilities.

00:35:14.953 --> 00:35:15.233
They do.

00:35:15.726 --> 00:35:19.547
PhDs, MAs, all in DNP manufacturing.

00:35:19.847 --> 00:35:25.247
So it's a really good job that they
get and they do a really good job.

00:35:25.967 --> 00:35:27.407
So you can do it.

00:35:27.407 --> 00:35:28.667
You just can't do it tomorrow.

00:35:28.787 --> 00:35:29.462
You need to think ahead.

00:35:30.032 --> 00:35:31.232
Susannah de Jager: Need proper policy.

00:35:32.312 --> 00:35:36.602
Now on the more cautionary side,
you and I have also talked about

00:35:36.902 --> 00:35:42.042
the dislocation between pricing and
valuation and how robust you need to be.

00:35:42.552 --> 00:35:46.542
Obviously we've touched upon your
approach strategically to a portfolio of

00:35:46.542 --> 00:35:48.732
assets to protect against some of that.

00:35:48.732 --> 00:35:52.902
But I'd love to hear from your
experience, just if somebody were

00:35:52.902 --> 00:35:54.372
listening and thinking, oh, great.

00:35:54.402 --> 00:35:58.052
Sounds like the streets are
paved with gold on the NASDAQ.

00:35:58.262 --> 00:36:02.162
Clearly, you need to really know
what you are in for there as well,

00:36:02.312 --> 00:36:04.052
and it's not all plain sailing.

00:36:05.677 --> 00:36:09.712
Zandy Forbes: Not at all plain
sailing, and there are, particularly in

00:36:09.712 --> 00:36:14.452
biotech, there are incredibly bullish
moments that may be too positive.

00:36:14.842 --> 00:36:17.392
Then negative moments,
which may be too negative.

00:36:17.392 --> 00:36:21.862
And when I say moments, these moments
could be years, not 10 minutes.

00:36:22.332 --> 00:36:24.492
Although 10 minutes can also be a moment.

00:36:24.892 --> 00:36:31.157
So they're incredibly negative moments and
there is in biotech, particularly small

00:36:31.157 --> 00:36:38.252
biotech, after COVID when there was a huge
amount of money put in, lots of companies

00:36:38.252 --> 00:36:44.432
started, were IPOing at high valuations,
way higher than ours and there were

00:36:44.432 --> 00:36:46.832
many companies that were being formed.

00:36:47.372 --> 00:36:50.192
There was a lot of money
put into the market.

00:36:50.462 --> 00:36:55.082
Maybe some of the companies were
too early, maybe their technology

00:36:55.592 --> 00:36:57.782
wasn't something that could survive.

00:36:57.992 --> 00:37:00.722
Maybe they never grew
into their valuations.

00:37:01.022 --> 00:37:07.575
There are many things, but after
COVID, as interest rates went up, the

00:37:07.575 --> 00:37:14.950
desire for money burning, not revenue
generating by biotechnology declined,

00:37:15.975 --> 00:37:23.738
and we saw a real decline in valuation
over that year, the subsequent year, and

00:37:23.738 --> 00:37:28.658
for small biotechs, cause this doesn't
include the big ones that make revenues

00:37:28.658 --> 00:37:30.128
or have drugs approved, et cetera.

00:37:30.128 --> 00:37:35.438
But for small pre-revenue biotechs,
it's been a very difficult three years

00:37:35.738 --> 00:37:41.018
because I would say last year, the
beginning of year we 2024, we thought

00:37:41.018 --> 00:37:41.918
everything was going to be okay.

00:37:43.208 --> 00:37:46.688
Everyone was coming into biotech at the
beginning of the year, and then, I think

00:37:46.688 --> 00:37:50.708
it was around February 12th or something,
inflation number came out in the

00:37:50.708 --> 00:37:54.473
second week of February, and it was up.

00:37:54.953 --> 00:37:59.003
And so the idea that the Fed was
going to cut rates three times in

00:37:59.003 --> 00:38:04.643
the year disappeared and all of these
small companies went down again,

00:38:04.943 --> 00:38:07.103
and so that was the second bad year.

00:38:07.373 --> 00:38:09.533
And interest rates never came down, right?

00:38:09.763 --> 00:38:15.853
Multiple bad years result in many
funds, which are biotech focused,

00:38:16.213 --> 00:38:21.958
have lost money, and so they're
in a position where it's very hard

00:38:22.258 --> 00:38:23.998
for them to make new investments.

00:38:24.298 --> 00:38:28.408
They need to support their own
companies because these are money

00:38:28.408 --> 00:38:33.058
burning companies and many of them have
really good ideas and good products

00:38:33.058 --> 00:38:35.308
and maybe even close to market.

00:38:35.358 --> 00:38:40.338
This year, again, beginning of the year,
and this is from many starts, beginning

00:38:40.338 --> 00:38:42.828
of the year, every markets are going up.

00:38:43.743 --> 00:38:53.193
And then, the leadership in the FDA
and other areas were announced and

00:38:53.193 --> 00:38:56.553
it was perceived as negative, right?

00:38:56.703 --> 00:39:01.953
Just perceived, and so
another hard year began.

00:39:03.363 --> 00:39:07.333
Now, I'll just mention why I said
perceived, from the perspective of

00:39:07.333 --> 00:39:13.483
reality, our interactions with the
FDA have been better than I've ever

00:39:13.483 --> 00:39:15.313
experienced in the last 10 years.

00:39:15.823 --> 00:39:17.143
Driven by science.

00:39:17.533 --> 00:39:19.003
Driven by rationale.

00:39:19.423 --> 00:39:27.028
Driven by real reviewers reading every
document and coming prepared to meetings,

00:39:27.448 --> 00:39:29.278
and we've been given designations.

00:39:29.278 --> 00:39:31.918
We've had excellent
conversations with the agencies.

00:39:32.338 --> 00:39:39.178
So there's a perception of the FDA
and there's the reality of the FDA

00:39:39.518 --> 00:39:44.705
and my experience of the FDA and
reality may lie somewhere in between.

00:39:45.005 --> 00:39:49.985
But that was a hit to biotech,
and in particular to companies

00:39:49.985 --> 00:39:51.545
that had certain types of drugs.

00:39:52.155 --> 00:39:59.575
I think without a massive recovery,
there is the opportunity at the moment

00:39:59.575 --> 00:40:07.525
for the big funds to look through this
wasteland and pick the diamonds in the

00:40:07.525 --> 00:40:16.105
rough because there isn't really a good
correlation between stock price and value.

00:40:16.135 --> 00:40:21.865
Like we have four late stage programs
and manufacturing as well as this

00:40:21.865 --> 00:40:26.245
future looking technology and many
preclinical programs, right, and other

00:40:26.245 --> 00:40:33.025
companies inside us, and our valuation
is not changed since IPO basically.

00:40:33.205 --> 00:40:34.075
It's a little bit higher.

00:40:34.615 --> 00:40:38.747
But we are an opportunity,
a diamond or an emerald.

00:40:38.747 --> 00:40:39.357
In the rough.

00:40:39.597 --> 00:40:44.097
And I know there are other ones and I do
believe that fund managers are starting

00:40:44.097 --> 00:40:49.227
to look at that, albeit really looking
at things that have something innovative.

00:40:49.677 --> 00:40:54.147
Susannah de Jager: Do you ever think that
your strategy of a portfolio of assets

00:40:54.147 --> 00:40:58.587
means that the individual value of each
of those is harder to perceive and that

00:40:58.907 --> 00:41:02.577
obviously eventually when they play
through, the value will be there, but

00:41:02.577 --> 00:41:04.082
that they can slightly cloud one another.

00:41:04.630 --> 00:41:06.130
Zandy Forbes: That's absolutely right.

00:41:07.190 --> 00:41:08.300
Couldn't be righter.

00:41:08.837 --> 00:41:16.067
I believe our valuation, is to some people
Parkinson's, to other people's Xerostomia,

00:41:16.697 --> 00:41:22.217
to other people the eye, to other people
the future pipeline and manufacturing.

00:41:23.147 --> 00:41:28.997
Any one of those alone more than
supports our current valuation.

00:41:29.454 --> 00:41:33.394
It's very hard for an
investor to value all of it.

00:41:33.454 --> 00:41:38.289
It becomes too much and I think
what you said is completely true.

00:41:38.704 --> 00:41:39.859
Susannah de Jager: Zandy, thank you.

00:41:40.009 --> 00:41:42.792
This has been an incredibly
wide ranging conversation.

00:41:42.792 --> 00:41:47.382
But really, really interesting and I
appreciate you coming to speak to us.

00:41:48.297 --> 00:41:50.817
Zandy Forbes: Well, I really
appreciate you asking me and it's

00:41:50.817 --> 00:41:52.437
been so interesting talking to you.

00:41:52.437 --> 00:41:53.689
So thank you so much.

00:41:54.374 --> 00:41:56.494
Susannah de Jager: Thanks for
listening to this episode of Oxford+,

00:41:56.964 --> 00:41:58.564
presented by me, Susannah de Jager.

00:41:58.844 --> 00:42:03.044
If you want to stay up to date with all
things Oxford+, please visit our website,

00:42:03.094 --> 00:42:07.814
oxfordplus.co.uk and sign up for our
newsletter so you never miss an update.

00:42:08.294 --> 00:42:11.594
Oxford+ was made in partnership
with Mishcon de Reya and is produced

00:42:11.594 --> 00:42:13.304
and edited by Story Ninety-Four.